Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00014690 · ClinicalTrials.gov registry record · Phase 2
ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00014690: Completed Phase 2 study, sponsored by AstraZeneca.
NCT00014690 is a Phase 2 study that has completed, run by AstraZeneca. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00014690, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining two or more drugs may kill more tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of different regimens of ZD9331 with or without topotecan in treating patients who have refractory or recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer.
Interventions
- DRUG topotecan hydrochloride
- DRUG plevitrexed
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-03 |
| Est. Completion | 2004-02 |
| Phase | Phase 2 |
What the finished NCT00014690 record still lists
NCT00014690 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which topotecan hydrochloride is the first listed.
NCT00014690 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00014690 about?
NCT00014690 is a clinical study titled "ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining two or more drugs may kill more tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of different regimens of ZD9331 with or without topotecan in t...
What is the current status of trial NCT00014690?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-03. Estimated completion is 2004-02.
What interventions are being tested in trial NCT00014690?
The interventions under investigation include: topotecan hydrochloride (DRUG), plevitrexed (DRUG).
Who is sponsoring clinical trial NCT00014690?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia